These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

182 related items for PubMed ID: 22999146

  • 1. FDA actions against health economic promotions, 2002-2011.
    Neumann PJ, Bliss SK.
    Value Health; 2012; 15(6):948-53. PubMed ID: 22999146
    [Abstract] [Full Text] [Related]

  • 2. FDA actions against misleading or unsubstantiated economic and quality-of-life promotional claims: an analysis of warning letters and notices of violation.
    Stewart KA, Neumann PJ.
    Value Health; 2002; 5(5):390-7. PubMed ID: 12201856
    [Abstract] [Full Text] [Related]

  • 3. A review of FDA warning letters and notices of violation issued for patient-reported outcomes promotional claims between 2006 and 2012.
    Symonds T, Hackford C, Abraham L.
    Value Health; 2014 Jun; 17(4):433-7. PubMed ID: 24969004
    [Abstract] [Full Text] [Related]

  • 4. Trouble Spots in Online Direct-to-Consumer Prescription Drug Promotion: A Content Analysis of FDA Warning Letters.
    Kim H.
    Int J Health Policy Manag; 2015 Aug 25; 4(12):813-21. PubMed ID: 26673465
    [Abstract] [Full Text] [Related]

  • 5. Food and Drug Administration surveillance of dermatology-related and nondermatology-related prescription drug advertising in the USA, 2000-2003.
    Cowden AL, Katz KA.
    Br J Dermatol; 2006 May 25; 154(5):950-8. PubMed ID: 16634900
    [Abstract] [Full Text] [Related]

  • 6. Changes in FDA enforcement activities following changes in federal administration: the case of regulatory letters released to pharmaceutical companies.
    Nguyen D, Seoane-Vazquez E, Rodriguez-Monguio R, Montagne M.
    BMC Health Serv Res; 2013 Jan 22; 13():27. PubMed ID: 23339419
    [Abstract] [Full Text] [Related]

  • 7. An analysis of the warning letters issued by the FDA to pharmaceutical manufacturers regarding misleading health outcomes claims.
    Chatterjee S, Patel HK, Sansgiry SS.
    Pharm Pract (Granada); 2012 Oct 22; 10(4):194-8. PubMed ID: 24155837
    [Abstract] [Full Text] [Related]

  • 8. Content Analysis of 2012-2019 FDA Warning Letters and Notices of Violations using the Economic, Clinical, and Humanistic Outcomes (ECHO) Model.
    Mohite N, Funtanilla V, Muzumdar J, Park T.
    Innov Pharm; 2021 Oct 22; 12(1):. PubMed ID: 34007685
    [Abstract] [Full Text] [Related]

  • 9. When Does FDAMA Section 114 Apply? Ten Case Studies.
    Neumann PJ, Saret CJ.
    Value Health; 2015 Jul 22; 18(5):682-9. PubMed ID: 26297097
    [Abstract] [Full Text] [Related]

  • 10. Health Claims About Cannabidiol Products: A Retrospective Analysis of U.S. Food and Drug Administration Warning Letters from 2015 to 2019.
    Wagoner KG, Lazard AJ, Romero-Sandoval EA, Reboussin BA.
    Cannabis Cannabinoid Res; 2021 Dec 22; 6(6):559-563. PubMed ID: 34142863
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Comparison of content of FDA letters not approving applications for new drugs and associated public announcements from sponsors: cross sectional study.
    Lurie P, Chahal HS, Sigelman DW, Stacy S, Sclar J, Ddamulira B.
    BMJ; 2015 Jun 10; 350():h2758. PubMed ID: 26063327
    [Abstract] [Full Text] [Related]

  • 13. Drug Advertising Violations: A Longitudinal Trend Analysis of FDA Enforcement Letters from 2005 to 2019.
    Zagrodney KAP, Sheikhan NY, Pinto A, Sheikhan T, Witek TJ.
    Pharmaceut Med; 2021 Jan 10; 35(1):31-38. PubMed ID: 33453042
    [Abstract] [Full Text] [Related]

  • 14. An Updated Review of Food and Drug Administration Warning and Untitled Letters for Clinical Outcome Assessment Claims Between 2013 and 2021.
    Sams L, Slagle AF, Symonds T, Antonova J, Globe D.
    Value Health; 2023 Dec 10; 26(12):1675-1680. PubMed ID: 37748736
    [Abstract] [Full Text] [Related]

  • 15. A Legislative/Legal History of Prescription Drug Advertising and Promotion Regulation.
    Li S, Gibbs I.
    J Pharm Pharm Sci; 2021 Dec 10; 24():381-389. PubMed ID: 34314671
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. FDA's expanding postmarket authority to monitor and publicize food and consumer health product risks: the need for procedural safeguards to reduce "transparency" policy harms in the post-9/11 regulatory environment.
    Roller ST, Pippins RR, Ngai JW.
    Food Drug Law J; 2009 Dec 10; 64(3):577-98. PubMed ID: 19999646
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Analysis of US Food and Drug Administration Warning Letters: False Promotional Claims Relating to Prescription and Over-the-Counter Medications.
    Salas M, Martin M, Pisu M, McCall E, Zuluaga A, Glasser SP.
    Pharmaceut Med; 2008 Mar 01; 22(2):. PubMed ID: 24353430
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.